fourth among men,4 and it is estimated that there will be approximately 84,870 new cases of bladder cancer in the U.S. in 2025.4 Historically, 75% of bladder cancer presents as NMIBC.5 In patients with high-risk NMIBC, intravesical BCG remains the...
This latest milestone builds upon the company's landmark first-in-human procedures reported in September and December of 2025. In up to nine-months follow-up of the initial four cases, the RoseDoc platform demonstrates exceptional efficacy, safety...
system. With more than 9 000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025..
sciences. This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with...
United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has...
said Pieter Muntendam MD, founder, President and CEO of SQ Innovation. "Following FDA approval in the United States in 2025, these European regulatory milestones reflect our commitment to bringing this transformative at-home therapy to patients...
for autoimmune diseases and inflammatory disorders. Cellenkos was granted US patent (US12472182B2) on November 18, 2025, for their technology covering "Compositions comprising regulatory t cells and methods of" producing and using them. Using its...
participants in the third quarter of 2026." Dr. Wu added, "Based on the positive clinical results announced in December 2025 from our 13-week U.S. Phase II study of ASC30 in participants with obesity or overweight, the Company expects to obtain the...
up with Cost Plus Drugs provides another option for cash-paying patients to access Eliquis directly. This follows the 2025 launch of a direct-to-patient offering through the BMS-Pfizer Alliance’s patient resource Eliquis 360 Support, which is also...
program will be featured at leading transplant and virology meetings in 2026, building on findings presented at the ASN in 2025. Alongside its core focus on polyomaviruses, Orthogon is advancing programs in additional areas of unmet need in...
Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring...
the no-union management policy remains unfulfilled. This discrepancy is evidenced by internal documents leaked in November 2025. "As extensively covered by South Korea's major broadcaster MBC, these documents revealed evidence of Unfair Labor...
member of Y-mAbs Therapeutics, where he was appointed CEO in 2023 and led until its acquisition by SERB Pharmaceuticals in 2025. He brings to the Convergent board decades of radiopharmaceutical experience, having served as President, Medical Group...
The launch of the Innovation Central Laboratory is the latest in a series of innovative developments from ARUP. In April 2025, ARUP launched a blood-based biomarker assay to determine whether cognitive decline symptoms in patients ages 60 years and...
anti-cancer treatments included an androgen receptor pathway inhibitor (ARPI) and androgen deprivation therapy (ADT). In 2025, the disease progressed further, and he was enrolled into the Cohort Expansion Phase of the SECuRE study with a baseline...
3 SMART trial — alongside data from the pivotal Phase 2b/3 CLEVER trial—supported the FDA approval of ENFLONSIA in June 2025 and subsequent global regulatory approvals. Interim data from RSV season 1 of the SMART trial were also presented at IDWeek...
of Libevitug began in 2018. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter,...
including bispecific and multi-specific antibodies, antibody-drug conjugates (ADCs), and fusion proteins. As of 2025, WuXi Biologics' integrated platform supports 945 projects, approximately 60% of which involve bi- and multi-specific antibodies,...
YouTube, and Facebook. *Source: US in-home wearable pump trial with 15 moms, 5-day usage + post-trial survey, October 2025. About Lansinoh®: For over 40 years, Lansinoh® has been building a community that understands what moms go through, creating...
new global headquarters in Singapore. The appointment follows a thoughtful and considered process. In early September 2025, Novotech’s former CEO Dr. John Moller informed employees of his intention to step down from the position at the end of last...
